Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?

ImmunityBio reported FY2025 net product revenues of $113 million for Anktiva, up ~700% YoY and beating the firm's earnings and sales estimates. Repeat prescribing and an ongoing BCG shortage are cited as primary demand drivers, and Anktiva secured EU and Saudi approvals in early‑2026, supporting near‑term international revenue upside. The company faces strong competition from Merck's Keytruda, BMS's Opdivo and Roche's Tecentriq and currently trades at a forward P/S of 33.86x versus an industry average of 2.00x (Zacks Rank #3).

Analysis

The biggest near-term structural lever for uptake isn’t clinical superiority alone but an idiosyncratic supply dynamic: treatments that require a co-administered biologic face a hard ceiling if that partner is scarce. That creates a non-linear demand curve where IO adoption can spike quickly in constrained markets but then plateau as treating physicians triage limited doses — peak revenue is therefore a function of both physician willingness and third‑party supply recovery timelines.

Incumbent oncology players have scale and channel power, but their incentives to race into a narrow, label‑constrained niche are muted unless pricing and reimbursement in major Western markets become demonstrably attractive. This opens an 18–24 month window where a smaller, agile commercial execution can capture disproportionate share regionally, after which margin compression and formulary battles will likely accelerate as payers push back and multi‑indication competitors deploy cross‑selling advantages.

Key catalysts to watch are operational rather than purely clinical: monthly dispensing cadence (percent repeat prescriptions), national BCG inventory updates, and the timing/details of country‑level reimbursement decisions in the EU. Tail risks that would flip the thesis quickly include rapid repair of BCG supply chains, an adverse real‑world safety signal, or a payor reference‑pricing decision that forces a sharp rebate concession; any of these can compress forward cash flows within 3–12 months.

Key Decisions for Investors

• Directional long: Buy IBRX 12–18 month LEAP call spread (buy nearer‑the‑money LEAP / sell higher strike LEAP) sized as 1–2% of portfolio. Rationale: capture adoption upside in the 12–18 month commercial window while capping downside; target 2–3x if repeat prescribing and EU rollouts scale. Max loss = premium paid; take profits at 100–150% or if shares rally >60% from entry.
• Hedge pair: Establish a paired trade long IBRX equity / short MRK (or BMY) equal dollar notional to isolate Anktiva adoption vs systemic oncology beta for a 6–12 month horizon. Use the short to finance put protection on IBRX or to reduce net exposure; exit if IBRX share gains >40% or if MRK/BMY announce competing label expansion.
• Protective collar for equity holders: Long IBRX equity + buy 9–12 month 30–40% OTM puts and sell nearer‑term calls to fund cost. Use this if you want asymmetric upside while limiting drawdown to ~25–30% over the next year (good around earnings or reimbursement readouts).
• Event‑driven short: Small, tactical short of IBRX (or buying short‑dated puts) ahead of any positive headline that looks priced for perfection — size small (0.5–1% portfolio). Exit or flip to long if repeat prescription metrics in two consecutive quarters exceed internal targets; risk: rapid short squeeze on positive adoption prints.
• Monitoring triggers (risk management): Reduce gross exposure by 50% if national BCG supply indicators show sustained improvement over 2 months, or if major EU payers mandate steep rebates; take full profits if company guidance implies >20% faster penetration than modeled over 12 months.